Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators.

J Am Coll Cardiol. 2017 Jan 17;69(2):176-185. doi: 10.1016/j.jacc.2016.10.055.

PMID:
28081827
2.

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators.

N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.

3.

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators.

JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734.

PMID:
26547357
4.

Synovial chondromatosis presenting as an epidural mass.

Mehra RN, Grigorov M, Pieper D.

Surg Neurol Int. 2015 Aug 31;6(Suppl 14):S388-90. doi: 10.4103/2152-7806.163961. eCollection 2015.

5.

Ivabradine in stable coronary artery disease without clinical heart failure.

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators.

N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.

6.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

7.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

8.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators.

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

9.

Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI: data from a multicentre registry.

Knot J, Kala P, Rokyta R, Stasek J, Kuzmanov B, Hlinomaz O, Bĕlohlavek J, Rohac FP, Petr R, Bilkova D, Djambazov S, Grigorov M, Widimsky P.

Cardiovasc J Afr. 2012 Oct;23(9):495-500. doi: 10.5830/CVJA-2012-053.

10.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

11.

Minimum information about a bioactive entity (MIABE).

Orchard S, Al-Lazikani B, Bryant S, Clark D, Calder E, Dix I, Engkvist O, Forster M, Gaulton A, Gilson M, Glen R, Grigorov M, Hammond-Kosack K, Harland L, Hopkins A, Larminie C, Lynch N, Mann RK, Murray-Rust P, Lo Piparo E, Southan C, Steinbeck C, Wishart D, Hermjakob H, Overington J, Thornton J.

Nat Rev Drug Discov. 2011 Aug 31;10(9):661-9. doi: 10.1038/nrd3503. Review.

PMID:
21878981
12.

Analysis of time course Omics datasets.

Grigorov MG.

Methods Mol Biol. 2011;719:153-72. doi: 10.1007/978-1-61779-027-0_7.

PMID:
21370083
13.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S.

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.

14.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators.

Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].

PMID:
20801500
15.

The misuse of clinical paths as an instrument for funding inpatient care in Bulgaria.

Vekov TY, Grigorov MV, Djambazov SN.

World Hosp Health Serv. 2009;45(3):10-2.

PMID:
20136028
16.

Intravenous platelet blockade with cangrelor during PCI.

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators.

N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629.

17.

Decrease in acute coronary syndrome mortality in Pleven district: implementation of scientific evidence into everyday practice.

Vekov TY, Grigorov MV, Georgiev VT, Djambazov SN, Groch L, Hlinomaz O, Sitar J, Rezek M.

World Hosp Health Serv. 2009;45(2):23-6.

PMID:
19761016
18.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M.

N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.

19.

Biomarkers of human gastrointestinal tract regions.

Comelli EM, Lariani S, Zwahlen MC, Fotopoulos G, Holzwarth JA, Cherbut C, Dorta G, Corthésy-Theulaz I, Grigorov M.

Mamm Genome. 2009 Aug;20(8):516-27. doi: 10.1007/s00335-009-9212-7. Epub 2009 Aug 27.

PMID:
19711126
20.

The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes.

Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KA, Goldberg RJ, Anderson FA Jr; Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators.

Am Heart J. 2009 Aug;158(2):193-201.e1-5. doi: 10.1016/j.ahj.2009.06.003.

PMID:
19619694

Supplemental Content

Loading ...
Support Center